Patrícia Scuracchio
A5004315909- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Blood donation and transfusion practices
- Blood groups and transfusion
- Blood transfusion and management
- SARS-CoV-2 detection and testing
- Hemoglobinopathies and Related Disorders
- Organ Donation and Transplantation
- Mosquito-borne diseases and control
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Erythrocyte Function and Pathophysiology
- Viral Infections and Outbreaks Research
- Diabetes and associated disorders
- Liver Disease and Transplantation
- Education during COVID-19 pandemic
- Healthcare Regulation
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Renal Transplantation Outcomes and Treatments
- Vector-borne infectious diseases
- Infection Control in Healthcare
- HIV/AIDS drug development and treatment
- Malaria Research and Control
- HIV/AIDS Research and Interventions
- COVID-19 and healthcare impacts
Hospital Sírio-Libanês
2013-2025
All India Institute of Medical Sciences
2021
Canadian Bio-Systems (Canada)
2021
World Health Organization Regional Office for South-East Asia
2021
Wuhan Blood Center
2021
Shaanxi Blood Center
2021
Tan Tock Seng Hospital
2021
Amsterdam UMC Location University of Amsterdam
2014
Institute for Transfusion Medicine
2014
University of Pittsburgh
2014
Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients.Mild/moderate COVID-19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and absence symptoms ≥14 days plus (a) age (18-60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no...
Malaria in Brazil is endemic the Amazon region, but autochthonous cases with low parasitaemia occur Atlantic Forest area of country. According to Brazilian legislation no test mandatory for blood donors from non-endemic areas. However if they have traveled malaria transmission regions are deferred six months before can donate. This report describes a transfusion-transmitted case Sao Paulo, Brazil, where one recipient received infected and developed disease. He lived Paulo had previous...
Abstract Introduction Little is known about the neutralizing (nAb) and binding antibody kinetics in COVID‐19 convalescent plasma donors, especially during first 100 days after disease onset. Materials Methods A cohort of previously RT‐PCR positive (detected by nasopharyngeal swab acute phase), male patients, all with mild symptoms, were enrolled serial blood sample collection for a longitudinal nAb titers anti‐nucleocapsid (NP) antibodies (IgM, IgG IgA) evaluation. NAbs detected cytopathic...
Abstract Background Blood donation is a safe process though reactions may still occur. We describe rare vascular complication in frequent donor, with improvements the collection aimed at avoiding future events. Methods A 63‐year‐old woman presented local pain and an apparent left arm 8 days after donation. Duplex ultrasound identified superficial liquid signs of arteriovenous fistula (AVF) between cubital vein arterial branch. computed tomography (CT)‐angio performed 1 day did not identify...
legend: 1: Provides CMV-negative and leucoreduced product; 2: provides product or CMV alone; 3: LR either pathogen-inactivated 4: practice unspecified unknown.a Refers to cases when mother is negative.b recipient donor are negative.
Blood groups and anti-A isohemagglutinin may be involved in susceptibility to SARS-CoV-2 infection.
Individual nucleic acid-amplification testing (NAT) was recently recommended by Brazilian legislation and has been implemented at some blood banks in the city of São Paulo, Brazil, an attempt to reduce transfusion transmission human immunodeficiency virus (HIV) hepatitis C viruses. This screening test can identify donations made during immunological window period before seroconversion. The impact this technology our donors routine studied. In all, 47 866 were tested from March 2004 until...
Abstract Background Current evidence regarding COVID‐19 convalescent plasma (CCP) transfusion practices is limited and heterogeneous. We aimed to determine the impact of use CCP in patients with previous circulating neutralizing antibodies (nAbs) COVID‐19. Methods Prospective cohort including 102 transfused ABO compatible on days 0–2 after enrollment. Clinical status was assessed using adapted World Health Organization (WHO) ordinal scale 0, 5, 14. The nAbs titration performed cytopathic...
COVID-19 high-titer CCP selection is a concern, because neutralizing antibody (nAb) testing requires sophisticated labs and methods. Surrogate tests are an alternative for measuring nAb levels in plasma bags, including those that pathogen-reduced.We studied panel consisting of 191 samples from convalescent donors tested by (CPE-VNT), obtained 180 donations (collection: March 20-January 21) 11 negative controls, with total 80 111 serum (71 amotosalen/UV treated), titers ranging to 10,240....
(1) Background: We reviewed the logistics of implementation pathogen reduction (PR) using INTERCEPT Blood System™ for platelets and experience with routine use clinical outcomes in patient population at Sírio-Libanês Hospital São Paulo, Brazil. (2) Methods: Platelet concentrate (PC), including reduced (PR-PC) production, inventory management, discard rates, blood utilization, were analyzed over 40 months before after PR implementation. Age distribution wastage rates compared 10 approval...
Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory coronavirus 2(SARS-CoV-2), has rapidly spread since its first declaration the World Health Organization (WHO) as a global pandemic in March 2020 [1]. Until vaccination started to be rolled out an increasing number of countries, different modalities treatment were deployed attempt combat this deadly virus but with limited efficacy so far [2]. Collection and use convalescent plasma for (COVID-19) (CCP) passive...
Abstract INTRODUCTION COVID-19 convalescent plasma (CCP) transfusion has emerged in the past months as an alternative approach to treat pneumonia cases of SARS-CoV-2. Current evidence regarding characteristics product, titer neutralizing antibodies (nAbs) transfused units, time onset intervention, and impact nAbs produced by patient are limited heterogeneous. MATERIAL AND METHODS We describe preliminary results 104 patients with severe due SARS-CoV-2 CCP at three medical centers Brazil. All...
(1) Background: We reviewed the logistics of implementation pathogen inactivation (PI) using INTERCEPT Blood System™ for platelets and experience with routine use clinical outcomes in patient population at Sírio-Libanês Hospital São Paulo, Brazil. (2) Methods: Platelet concentrate (PC), including reduced (PR-PC) production, inventory management, discard rates, blood utilization, were analyzed over 40 months before after PI implementation. Age...
Vox SanguinisVolume 116, Issue 10 p. e71-e120 International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Responses Arwa Z. Al-Riyami, Al-Riyami [email protected] orcid.org/0000-0001-8649-0650 Sultan Qaboos University Hospital, Seeb, Sultanate OmanSearch for more papers by this authorThierry Burnouf, Thierry Burnouf orcid.org/0000-0002-0507-9243 Search authorMark Yazer, Corresponding Author Mark Yazer Vitalant, Pittsburgh, PA, USASearch authorDarrell Triulzi, Darrell...
Abstract Introduction A cohort of COVID-19 convalescent volunteers allowed the study neutralizing (nAb) and ligand antibodies kinetics by providing sequential samples during a median 100 days after onset disease. Material Methods previously RT-PCR+ve (detected nasopharyngeal swab acute phase), male patients, all with mild symptoms, were enrolled on serial blood sample collection for evaluation longitudinal nAb titers anti-nucleocapsid (NP) (IgM, IgG IgA). Nabs detected cytopathic...